Cardima Revelation Tx re-submission
This article was originally published in The Gray Sheet
Executive Summary
Amended PMA for paroxysmal atrial fibrillation treatment with linear ablation catheter is submitted to FDA Jan. 20, roughly seven months after the agency denied market go-ahead. "Additional data and analysis" included in the re-submission respond to efficacy concerns raised during a May Circulatory System Devices Panel meeting that resulted in a unanimous vote against approval. The amendment follows a Jan. 9 FDA guidance for catheter ablation systems treating AF, recommending 12-month follow-up (1"The Gray Sheet" Jan. 19, 2004, p. 7)...
You may also be interested in...
Catheter Ablation Trial Criteria For AF Therapy Clarified In FDA Guidance
Commercialization of CryoCath's catheter ablation system to treat atrial fibrillation could be delayed up to six months due to FDA follow-up data recommendations
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.